Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PureTech Health ADR Representing 10 Ord Shs PRTC

Healthcare Biotechnology
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European... see more

Recent & Breaking News (NDAQ:PRTC)

PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share

Business Wire May 20, 2024

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Business Wire May 9, 2024

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Business Wire May 7, 2024

PureTech Announces Annual Results for Year Ended December 31, 2023

Business Wire April 25, 2024

PureTech Health: Notice of Results

Business Wire April 18, 2024

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

Business Wire April 16, 2024

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

Business Wire April 11, 2024

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Business Wire April 9, 2024

PureTech Proposes $100 Million Capital Return

Business Wire March 19, 2024

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

Business Wire March 18, 2024

PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia

Business Wire March 13, 2024

PureTech to Present at Two Upcoming Investor Conferences

Business Wire February 27, 2024

PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan

Business Wire February 27, 2024

PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2024

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Business Wire December 22, 2023

PureTech Year End Update and Outlook for 2024

Business Wire December 20, 2023

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Business Wire December 7, 2023

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Business Wire November 29, 2023

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Business Wire November 17, 2023

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

Business Wire November 14, 2023